Last day of trading with unit rights in Lumito

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]

The subscription period in Lumito’s issue of warrants begins today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]

Lumito publishes prospectus in connection with issue of warrants

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]

Lumito notifies changes to terms for the issue of free-of-charge warrants

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]

Lumito signs an agreement with Uniogen Oy

Lumito AB and the Finnish company Uniogen Oy have signed a cooperation agreement for the production of Lumito’s immunohistochemical reagent kit, SCIZYS Erbium Kit. The reagent kit is part of Lumito’s product offering and is based on upconverted nanoparticles. Since June 2022, Lumito has had a Letter of Intent in place with Uniogen Oy (formerly […]

Successful results from a pre-study completed in collaboration with Umeå University, Sweden, shows that Lumito’s technique offers better possibilities compared with other immunohistochemical methods

A now completed pre-study, initiated at the beginning of this year in collaboration with a research group at Umeå University in Sweden led by Assistant Professor Daniel Öhlund has yielded successful results. The research group intended to identify how Lumito's UCNP (Up-Converting Nano Particles) technology could be used to improve the ability to visualise protein […]

Images of high and stable quality offer excellent assessment possibilities

Lumito’s objective is to create high-quality stainings of tissue sections and corresponding imaging. A key effort has been to achieve a repeatable and robust staining methodology that can generate imaging that is optimal for a digital, visual evaluation. These objectives have now been achieved, according to Dr. Bo Holmqvist. Bo Holmqvist (CSO, Imagene-iT AB) has […]

Earlier quarterly report in Lumito AB (publ)

Lumito AB (publ) hereby announces that the Board of Directors has decided to bring forward the company's report for quarter 3, 2021 to 20 October 2021, as the compilation work has progressed faster than expected and the auditors have reviewed the report. The Company's financial calendar has been updated and can be found here. For […]